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Association of Novel Biomarkers of Cardiovascular Stress With Left
Ventricular Hypertrophy and Dysfunction: Implications for Screening
Vanessa Xanthakis, PhD; Martin G. Larson, ScD; Kai C. Wollert, MD; Jayashri Aragam, MD, FACC; Susan Cheng, MD; Jennifer Ho, MD;
Erin Coglianese, MD; Daniel Levy, MD, FACC; Wilson S. Colucci, MD, FACC; G. Michael Felker, MD, FACC;
Emelia J. Benjamin, MD, ScM, FACC; James L. Januzzi, MD, FACC; Thomas J. Wang, MD, FACC; Ramachandran S. Vasan, MD, FACC
Background-—Currently available screening tools for left ventricular (LV) hypertrophy (LVH) and systolic dysfunction (LVSD) are
either expensive (echocardiography) or perform suboptimally (B-type natriuretic peptide [BNP]). It is unknown whether newer
biomarkers are associated with LVH and LVSD and can serve as screening tools.
Methods and Results-—We studied 2460 Framingham Study participants (mean age 58 years, 57% women) with measurements of
biomarkers mirroring cardiac biomechanical stress (soluble ST-2 [ST2], growth differentiation factor-15 [GDF-15] and high-sensitivity
troponin I [hsTnI]) and BNP. We deﬁned LVH as LV mass/height2 ≥the sex-speciﬁc 80th percentile and LVSD as mild/greater
impairment of LV ejection fraction (LVEF) or a fractional shortening <0.29. Adjusting for standard risk factors in logistic models, BNP,
GDF-15, and hsTnI were associated with the composite echocardiographic outcome (LVH or LVSD), odds ratios (OR) per SD increment
in log-biomarker 1.29, 1.14, and 1.18 (95% CI: 1.15 to 1.44, 1.004 to 1.28, and 1.06 to 1.31), respectively. The C-statistic for the
composite outcome increased from 0.765 with risk factors to 0.770 adding BNP, to 0.774 adding novel biomarkers. The continuous
Net Reclassiﬁcation Improvement was 0.212 (95%CI: 0.119 to 0.305, P<0.0001) after adding the novel biomarkers to risk factors plus
BNP. BNP was associated with LVH and LVSD in multivariable models, whereas GDF-15 was associated with LVSD (OR 1.41, 95% CI:
1.16 to 1.70), and hsTnI with LVH (OR 1.22, 95% CI: 1.09 to 1.36). ST2 was not signiﬁcantly associated with any outcome.
Conclusions-—Our community-based investigation suggests that cardiac stress biomarkers are associated with LVH and LVSD but
may have limited clinical utility as screening tools. ( J Am Heart Assoc. 2013;2:e000399 doi: 10.1161/JAHA.113.000399)
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T he high lifetime risk of heart failure (HF) combined withthe aging population has led to a dramatic rise in HF
prevalence worldwide.1,2 Up to half of HF patients have a
preserved left ventricular (LV) ejection fraction (HFPEF),
whereas the remainder has a reduced ejection fraction
(HFREF). Both forms of HF are associated with substantial
morbidity, mortality, and cost to the health care system.3–5
Thus, preventing HF is critical, and attention has turned
toward screening for HF risk by identifying “high-risk”
individuals (Stage A in the American Heart Association
[AHA]/American College of Cardiology [ACC] classiﬁcation
schema).6,7 Myocardial damage leading to LV systolic
dysfunction (LVSD) is the primary precursor to HFREF, and
LV hypertrophy (LVH) due to hypertension is the major
antecedent of HFPEF.8,9 Therefore, LVH and LVSD represent
key preclinical phenotypes (Stage B HF)7 that can be screened
for within the community. Indeed, HF meets several of the
criteria for a “screenable” condition: its prevalence is high, its
incidence is rising, and treatment is available for its preclinical
stages (ie, LVSD, and LVH on the basis of hypertension).10,11
However, the high prevalence of hypertension and relatively
lower prevalence of myocardial infarction (MI) among
older adults renders these 2 risk factors inadequate for
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differentiating high-risk from low-risk individuals. Additionally,
echocardiography is expensive and its routine use for
screening the general population for HF risk is neither
feasible nor likely to be cost effective.10,11 Consequently,
investigators have assessed the utility of biomarkers for
screening for LVH and LVSD. Clinical risk scores used for
predicting HF and existing biomarkers (such as circulating
levels of the B-type natriuretic peptide [BNP]) are associated
with LVH and LVSD, yet perform suboptimally for community-
wide screening for HF risk.12 The recent availability of novel
biomarkers that mirror cardiac biomechanical stress, notably
ST2, growth differentiation factor 15 (GDF-15), and high-
sensitivity troponin I (hsTnI), has generated the possibility that
a combination of circulating biomarkers may be associated
with LVH and LVSD, and may serve as a screening tool
(beyond clinical risk factors and BNP). People with LVH and
LVSD, identiﬁed via such an initial biomarker screening
strategy, could then undergo conﬁrmatory echocardiography.
We hypothesized that higher circulating levels of ST2, GDF-
15, and hsTnI are associated with a greater prevalence of LVH
or LVSD, and that a combination of these biomarkers with
BNP and clinical risk factors may have sufﬁciently robust
performance characteristics to serve as a screening tool for
LVH and LVSD in the community. We tested our hypotheses in
the large community-based Framingham Heart Study sample.
Methods
Study Sample
The study design and methods of the Framingham Heart Study
have been described in detail at http://www.framingham
heartstudy.org.13 We included Framingham Offspring partici-
pants who attended the sixth examination cycle (1995–1998)
when routine echocardiography was performed. Of 3532
attendees, 1072 participants were excluded for the following
reasons: non-available biomarker levels (n=49), inadequate
echocardiographic information (n=872), serum creatinine
levels ≥2 mg/dL (n=21), history of heart failure (n=35), or
missing covariate information (n=95). The study protocols were
approved by the Boston University Medical Center Institutional
Review Board. All participants provided written informed
consent.
Echocardiographic Measurements
All attendees underwent standardized 2D transthoracic echo-
cardiographywith Doppler color ﬂow imaging. A sonographer or
a cardiologist (experienced in echocardiography), blinded to
clinical information and biomarker results, read all echocardio-
grams. The reproducibility of echocardiographicmeasurements
was excellent.14 Interobserver variability ranged from 0.9% to
5% for LVDD, from 2% to 2.9% for diastolic posterior wall
thickness, from 3.6% to 6.5% for the interventricular septum in
diastole, and from 0.8% to 4% for calculated LV mass.
Corresponding ﬁgures for intraobserver variability ranged from
0.3% (LVDD) to 4% (interventricular septal thickness).14 Digital
M-mode measurements from ≥3 cardiac cycles were averaged
to estimate LV internal dimensions in end-systole and end-
diastole, and thicknesses of the interventricular septum and LV
posterior wall at end-diastole (in accordance with the American
Society of Echocardiography [ASE] guidelines).15 Fractional
shortening (FS) was calculated using LV internal dimensions at
end-diastole and end-systole.
In all participants, visual assessment of LV global systolic
function was performed in multiple views to estimate the LV
ejection fraction (LVEF), which was categorized as normal
(LVEF >0.55), borderline (LVEF 0.51 to 0.55), mildly reduced
(LVEF 0.41 to 0.50), moderately diminished (LVEF 0.31 to
0.40), or severely impaired (LVEF ≤0.30). The accuracy of the
aforementioned estimation of LVEF has been validated in prior
reports.16 Both the qualitative variable LVEF and the quanti-
tative variable FS were used to deﬁne LV systolic dysfunc-
tion12 (ie, the presence of either abnormal LVEF or abnormal
FS) because they provide complementary information: the
former may not be sensitive for detecting subtle alterations in
LV systolic function whereas the latter focuses on the base of
the heart (and may miss diminished LV contractility in other
regions).
Biomarker Measurements
Blood samples were collected after an overnight fast17 and
stored at 70°C until assayed. Although N-terminal pro-atrial
natriuretic peptide (NT-ANP) levels were also available at the
sixth examination cycle, we focused on BNP in the present
investigation given our previous report,12 which demonstrated
that BNP yielded better discrimination statistics for LVSD and
LVH relative to NT-ANP. BNP was measured using the Shionogi
assay,12 ST2 using a second-generation, high-sensitivity
enzyme-linked immunosorbent assay (Critical Diagnostics,
detection limit 2 ng/mL), GDF-15 using an automated, pre-
commercial electrochemilluminescent immunoassay (Roche
Elecsys, detection limit of <10 ng/L), and hsTnI using an
ultrasensitive immunoassay with a novel, single-molecule
counting technology (Singulex, detection limit is 0.2 pg/mL,
range 0.5 to 70 pg/mL). The interassay imprecisions for
GDF-15 were 2.3% and 1.8% at GDF-15 concentrations of 1100
and 17 200 ng/L, respectively. The interassay coefﬁcient of
variation (CV) ranged from 8% to 10%. The lower QC control for
hsTnI provided an average value of 4.71 pg/mL with an
interassay CV of 10%. The higher QC control provided an
average value of 19.05 pg/mL with an interassay CV of 8%. The
intra- and interassay coefﬁcients of variation for ST2 were <4%.
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Statistical Analysis
We natural-logarithmically transformed all biomarkers to
stabilize their distributions and reduce inﬂuence from extreme
biomarker values. We also used this transformation to be
consistent with our prior approach for some of these
biomarkers.12
We deﬁned 3 echocardiographic outcomes of interest12:
1. LVH_80, deﬁned as a value of LVM (left ventricular mass)/
height2 ≥the sex-speciﬁc 80th percentile value.
2. Mild/greater LVSD (LVSD_MILDGR), deﬁned as the pres-
ence of mild or greater degree of impairment of LVEF on
2-dimensional (2D) assessment of the echocardiogram, or
an M-mode FS <0.29 (corresponding to an LVEF ≤0.50).
3. Moderate/severe LVSD (LVSD_MODSEV), deﬁned as the
presence of moderate or severe degree of impairment of
LVEF on 2D assessment, or a FS <0.22 (corresponding to
an LVEF ≤0.40).
Additionally, we performed analyses using the ASE cut
points (LVM/height ≥127 g/m in men and ≥100 g/m in
women)15 to deﬁne LVH. To minimize multiple statistical
testing, we deﬁned a composite variable (presence of LVH_80
or mild/greater LVSD, corresponding to Stage B HF) and its
components as our primary outcomes, while moderate/severe
LVSD served as a secondary outcome (given its much lower
prevalence). The composite outcome was chosen because it is
desirable to identify a set of screening biomarkers that can
identify both LVH and LVSD, which would then have the
potential of preventing both HFPEF and HFREF.
Analysis of the composite echocardiographic outcome
We considered the following clinical risk factors previously
associated with either component of the composite outcome:
age, sex, body mass index (BMI), presence of MI, hypertension
status (deﬁned as systolic/diastolic blood pressure ≥140/
90 mm Hg, respectively, or use of antihypertensive treat-
ment), diabetes status, alcohol consumption, and the pres-
ence of atrial ﬁbrillation (AF) or valve disease. We performed
stepwise logistic regression analysis on these risk factors
using P=0.1 as the retention criterion to develop an initial
model. Accounting for selected clinical risk factors, we then
performed stepwise logistic regression analysis on the
biomarkers (BNP, GDF-15, ST2, and hsTnI) relating them to
the presence of the composite outcome. We also examined
performance characteristics of the biomarker combinations
with BNP and with clinical risk factors to assess their
incremental utility. We used 2 metrics to characterize
performance characteristics of the novel biomarkers
over BNP plus standard clinical risk factors: the increment
in the C-statistic (area under the receiver operating charac-
teristic curve [ROC]) upon adding the novel biomarkers, and
the continuous Net Reclassiﬁcation Improvement (NRI)18; NRI
values <0.2 are considered weak, those 0.4 are considered
intermediate, and values of 0.60 are considered strong.19
We applied the ﬁnal models to assess the predictive ability of
these novel biomarkers in the following clinical subgroups: ≥65
and <65 years; with and without hypertension; and with
and without prior MI. We evaluated individuals with an MI,
although they are likely to have an echocardiogram on a routine
basis, so that we obtain an estimate of the performance of
the biomarkers in the setting of prior myocardial damage.
Individual echocardiographic outcomes (LVH_80 and
LVSD)
We repeated the stepwise procedure separately for all 3
outcomes and created a ﬁnal set of risk factors combining the
statistically signiﬁcant variables from the 3 separate stepwise
procedures. We then performed a stepwise regression analysis
on the 4 biomarkers of interest for each outcome separately,
forcing in the ﬁnal set of risk factors identiﬁed above. We
evaluated the NRI and the increment in the C-statistic. These
analyses were repeated for the clinical subgroups. All analyses
were performed using SAS software version 9.2.20
A 2-sided value of P<0.05 was considered statistically
signiﬁcant. The authors had full access to the data and take
responsibility for its integrity. All authors have read and
agreed to the manuscript as written.
Results
Our sample consisted of middle-aged to older participants, with
a moderate prevalence of hypertension (Table 1). We observed
weak correlations among the novel biomarkers (Table 2).
Predictive Utility of Novel Biomarkers for the
Composite Echocardiographic Outcome
Of 2460 participants, 574 (23%) had either LVH_80 or mild/
greater LVSD, of whom 298 were women. Age, BMI, presence
of MI, hypertension status, diabetes status, presence of AF,
and valve disease were associated with the composite
outcome; these were used in all multivariable models. After
forcing in the clinical risk factors, the composite outcome was
associated with circulating concentrations of BNP, GDF-15,
and hsTnI (P<0.05 for each, Table 3), but not ST-2. Compared
with a model containing only risk factors (C=0.765), the
discrimination of the model increased to 0.770 upon adding
BNP, and to 0.774 with the further addition of GDF-15 and
hsTnI (Table 4). The addition of these 2 novel biomarkers
resulted in a statistically signiﬁcant NRI (Table 4).
Table 5 shows the number of people with a composite
outcome within each clinical subgroup. Plasma BNP was
associated with the composite outcome in all subgroups
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(Table 6). Additionally, GDF-15 was associated with the com-
posite outcome among people without an MI and in those
<65 years old, whereas hsTnI showed an association with the
composite outcome among those with and without anMI; those
<65 years old; and those with hypertension (Table 6). Although
the increase in the C-statistic was not statistically signiﬁcant
with the addition of the 2 novel biomarkers (data not shown), we
observed a statistically signiﬁcant NRI for most subgroups
(Table 7).
Predictive Utility of Novel Biomarkers for the
Individual Echocardiographic Outcomes
The number of participants with each individual outcome is
shown in Table 5. The combination of the statistically
signiﬁcant clinical covariates from the separate stepwise
regression analyses for each individual outcome included age,
sex, BMI, presence of MI, hypertension status, diabetes
status, presence of AF, and valve disease; these variables
were used in all multivariable models for each outcome.
In the full sample, BNP was associated with LVSD and LVH,
after adjusting for clinical risk factors. GDF-15 was associated
with mild/greater LVSD, whereas hsTnI was associated with
LVH_80 (Table 3). ST2 was not associated with any echo-
cardiographic outcome. The C-statistic of the model did not
signiﬁcantly increase with the addition of the biomarkers to the
risk factors plus BNP for any outcome, whereas the NRI was
statistically signiﬁcant for both LVH_80 and LVSD (Table 4),
with the magnitude in the weak-to-intermediate range.
In subgroup analyses, BNP was associated with all
outcomes among most subgroups, after adjusting for risk
factors. Associations among GDF-15, hsTnI, and the out-
comes varied across subgroups (Table 6). The addition of
these 2 biomarkers did not result in signiﬁcant increases in
the C-statistic for the subgroups as compared to the use of
risk factors plus BNP (data not shown); however, we observed
statistically signiﬁcant NRI for LVH_80 among all subgroups
and for mild/greater LVSD among most subgroups (Table 7).
In analyses modeling echocardiographic traits as continu-
ous variables, BNP was associated with LVM, LVDD, and
LVDS; hsTnI with both LVM and LVWT; and GDF-15 with LVWT
(P<0.05 for all).
Discussion
The use of single biomarkers (including BNP) for screening for
LVH and LVSD in the general population has proven to be
Table 2. Age- and Sex-Adjusted Pearson Correlation
Coefﬁcients Among the Novel Biomarkers
With Each Other and With BNP
Log ST2 Log hsTnI Log BNP
Log GDF-15 0.20 (<0.0001) 0.12 (<0.0001) 0.11 (<0.0001)
Log ST2 0.08 (<0.0001) 0.05 (0.009)
Log hsTnI 0.13 (<0.0001)
Values are sample Pearson correlation coefﬁcients (P value). BNP indicates B-type
natriuretic peptide; GDF-15, growth differentiation factor-15; hsTnI, high-sensitivity
troponin I.
Table 1. Characteristics of Study Sample
Variable Men (N=1063) Women (N=1397)
Clinical characteristics
Age, y 5810 589
Systolic blood
pressure, mm Hg
12917 12620
Diastolic blood
pressure, mm Hg
779 749
Body mass index,
kg/m2
28.03.9 26.85.1
Hypertension, % 42.8 34.7
Hypertension
treatment, %
29.9 21.7
Diabetes, % 12.9 7.7
Prevalent
myocardial
infarction, %
6.4 0.9
Valve disease, % 3.3 2.4
Prevalent atrial
fibrillation, %
3.7 0.8
Biochemical features
BNP, pg/mL 6.1 (4.0, 15.7) 9.6 (4.0, 19.4)
GDF-15, ng/L 1016 (792, 1336) 991 (799, 1253)
hsTnI, pg/mL 1.6 (1.03, 2.62) 1.12 (0.78, 1.86)
sST2, ng/mL 23.36 (19.12, 28.9) 18.38 (14.96, 22.73)
Echocardiographic characteristics
LV mass (indexed
to height), g/m2
80th percentile
90th percentile
62.714.3
72.9
81.2
53.612.2
63.1
69.5
Fractional
shortening
0.350.06 0.380.05
Mild/greater
LV systolic
dysfunction, %
9.7 2.8
Moderate-to-severe
LV dysfunction, %
4.1 0.5
Values are meanSD for age, systolic and diastolic blood pressure, body mass index, LV
mass, and fractional shortening, or median (Q1, Q3) for BNP, GDF-15, hsTnI, and sST2.
Fractional shortening, a measure of basal LV systolic function, was calculated as: FS (%)=
[LVID at end-diastoleLVID at end-systole]/LVID at end-diastole. BNP indicates B-type
natriuretic peptide; GDF, growth differentiation factor; hsTnI, high-sensitivity troponin I;
LV, left ventricular; LVID, LV internal dimension; sST2, soluble ST2.
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suboptimal in prior studies.12 We recently showed that
multiple biomarkers reﬂecting cardiac biomechanical stress
in this cohort of individuals predicted incident HF (AHA/ACC
Stage C/D).17 Accordingly, we examined if these biomarkers
were associated with LVH and LVSD, and could serve as
potential screening tools (for AHA/ACC Stage B). To our
knowledge, investigations evaluating multiple novel biomar-
kers mirroring cardiac stress for associations with and
community screening for the presence of LVH and LVSD are
sparse.21 Previous studies12 evaluating biomarkers for
screening for LVH or LVSD focused on the increment in the
C statistic as the sole criterion for assessing their utility, and
did not investigate the NRI that provides complementary
information. Therefore, we evaluated 3 novel biomarkers for
their associations with LVH and LVSD and their use for
screening purposes in a large community-based sample. We
also evaluated their performance in high-risk subgroups to
examine the premise that any strategy using these biomar-
kers could selectively target groups of individuals in whom the
screening yield may be maximal, thereby rendering these
biomarkers cost effective.
Principal Findings
Circulating concentrations of BNP, GDF-15, and hsTnI were
associated with the composite outcome. BNP was associated
with both LVH and LVSD, while GDF-15 and hsTnI were
associated with LVSD and LVH, respectively. ST2 was not
associated with any outcome. In secondary analyses, only BNP
was associated with moderate/severe LVSD. The combination
of GDF-15 and hsTnI minimally increased themodel’s predictive
utility for the composite outcome, as quantiﬁed by the NRI,
compared to amodel with risk factors and BNP. Analyses of LVH
and LVSD as separate outcomes showed similar patterns to
that for the composite outcome. Analyses within clinical
subgroups suggested an improvement in predictive utility for
most subgroups, using the NRI; however, the clinical interpre-
tation of a statistically signiﬁcant NRI is not as clear.
Table 3. Multivariable-adjusted Association of Statistically Signiﬁcant Biomarkers With Prevalence of Each Echocardiographic
Outcome
Composite (574/2460)† LVH_80 (489/2460)† LVSD_MILDGR (142/2460)† LVSD_MODSEV (51/2460)†
BNP 1.29 (1.15 to 1.44)** 1.25 (1.11 to 1.41)** 1.43 (1.17 to 1.73)** 1.79 (1.30 to 2.47)**
GDF-15 1.14 (1.004 to 1.28)* NS 1.41 (1.16 to 1.70)** NS
hsTnI 1.18 (1.06 to 1.31)* 1.22 (1.09 to 1.36)** NS NS
Values represent odds ratios (95% conﬁdence intervals) per 1 SD increment in log-biomarker. ST2 was not signiﬁcantly associated with any outcome. BNP indicates B-type natriuretic
peptide; GDF-15, growth differentiation factor-15; hsTnI, high-sensitivity troponin I; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; LVSD_MILDGR, mild/
greater LVSD; LVSD_MODSEV, moderate/severe LVSD; NS, no statistically signiﬁcant association.
*P<0.05, **P<0.001.
†Number of outcomes/number at risk.
Table 4. Incremental Utility of Biomarkers Over Clinical Risk Factors
Composite LVH_80 LVSD_MILDGR LVSD_MODSEV
C-statistic
Standard risk factors (1) 0.765 (0.742 to 0.788) 0.778 (0.755 to 0.801) 0.763 (0.714 to 0.812) 0.925 (0.892 to 0.958)
Standard risk factors+BNP (2) 0.770 (0.747 to 0.793) 0.783 (0.760 to 0.806) 0.769 (0.722 to 0.817) 0.931 (0.897 to 0.965)
Standard risk factors+biomarkers* (3) 0.774 (0.751 to 0.796) 0.786 (0.763 to 0.808) 0.782 (0.736 to 0.828) N/A
P Value for difference (1 vs 3) 0.03 0.03 0.14 0.40
P Value for difference (2 vs 3) 0.13 0.20 0.15 N/A
NRI
NRI (1 vs 3) 0.220 (0.127 to 0.313) 0.246 (0.148 to 0.345) 0.395 (0.227 to 0.562) 0.505 (0.237 to 0.773)
NRI (2 vs 3) 0.212 (0.119 to 0.305) 0.243 (0.145 to 0.340) 0.207 (0.037 to 0.376) N/A
P Value for NRI (1 vs 3) <0.0001 <0.0001 <0.0001 0.0004
P Value for NRI (2 vs 3) <0.0001 <0.0001 0.02 N/A
BNP indicates B-type natriuretic peptide; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; LVSD_MILDGR, mild/greater LVSD; LVSD_MODSEV, moderate/
severe LVSD; N/A, non-applicable, since models (2) and (3) were identical for LVSD_MODSEV; NRI, net reclassiﬁcation improvement.
*Model includes risk factors, BNP, and the biomarker that was signiﬁcantly associated with each outcome.
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Comparison with the Published Literature
Several investigations have reported that circulating BNP is a
suboptimal screening tool for LVH and LVSD.12,22 Other novel
biomarkers have been evaluated as screening tools, but
none has been proven to detect HF precursors. For example,
blood galectin-3, a marker of myocardial ﬁbrosis, has been
previously evaluated by our group but did not show an
association with LVH or LVSD after adjustment for risk
factors.23 In contrast, investigators have studied midregional
proadrenomedullin in relation to LVH and LV volumes and
observed an association of higher levels with LVH and greater
cardiac volumes.23–25 We did not measure this biomarker.
Given our recent data showing substantial HF risk prediction
Table 6. Association of Biomarkers With Prevalence of the Composite Echocardiographic Outcome Within Clinical Subgroups
Biomarker Full Sample
MI Status Age, y HTN Status
With MI Without MI ≥65 <65 With HTN Without HTN
Composite outcome
BNP 1.29**
(1.15 to 1.44)
2.28*
(1.22 to 4.25)
1.25**
(1.12 to 1.41)
1.37**
(1.14 to 1.64)
1.29**
(1.12 to 1.49)
1.31**
(1.13 to 1.52)
1.26*
(1.05 to 1.50)
GDF-15 1.14*
(1.004 to 1.28)
N/A 1.14*
(1.01 to 1.30)
N/A 1.19*
(1.03 to 1.37)
N/A N/A
hsTnI 1.18*
(1.06 to 1.31)
2.20*
(1.11 to 4.37)
1.15*
(1.03 to 1.29)
N/A 1.25**
(1.09 to 1.42)
1.26*
(1.08 to 1.47)
N/A
Mild/Greater LVSD
BNP 1.43**
(1.17 to 1.73)
2.17*
(1.31 to 3.62)
1.31*
(1.05 to 1.62)
1.43*
(1.04 to 1.97)
1.41*
(1.10 to 1.80)
1.57**
(1.21 to 2.05)
N/A
GDF-15 1.41**
(1.16 to 1.70)
N/A 1.55**
(1.27 to 1.89)
N/A 1.40*
(1.12 to 1.75)
1.47*
(1.15 to 1.88)
N/A
Moderate/Severe LVSD
BNP 1.79**
(1.30 to 2.47)
1.66*
(1.01 to 2.74)
1.85*
(1.22 to 2.81)
1.66*
(1.06 to 2.59)
2.12*
(1.35 to 3.32)
2.01**
(1.37 to 2.96)
N/A
LVH (exceeding the sex-specific 80th percentile of height-indexed LV mass)
BNP 1.25**
(1.11 to 1.41)
N/A 1.24**
(1.09 to 1.40)
1.40**
(1.17 to 1.68)
1.27*
(1.08 to 1.49)
1.27*
(1.09 to 1.48)
1.24*
(1.02 to 1.50)
hsTnI 1.22**
(1.09 to 1.36)
2.93*
(1.48 to 5.80)
1.17*
(1.04 to 1.32)
N/A 1.29**
(1.12 to 1.48)
1.33**
(1.13 to 1.56)
N/A
Values represent odds ratios (95% conﬁdence intervals) per 1 SD increment in log-biomarker. ST2 was not associated with any outcome. BNP indicates B-type natriuretic peptide; GDF-15,
growth differentiation factor-15; hsTnI, high-sensitivity troponin I; HTN, hypertension; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; N/A, no statistically signiﬁcant
association.
*P<0.05, **P<0.001.
Table 5. Numbers of Individuals With Outcomes in Clinical Subgroups of Participants
Subgroups/Echo Abnormality Sample Size Composite Outcome Mild/Greater LVSD Moderate/Severe LVSD
LVH Deﬁned as Exceeding the
Sex-speciﬁc 80th Percentile
Full sample 2460 574 (23.3) 142 (5.8) 51 (2.1) 489 (19.9)
With MI 79 55 (69.6) 41 (51.9) 25 (31.6) 34 (43.0)
Without MI 2379 517 (21.7) 99 (4.2) 24 (1.0) 454 (19.1)
Age ≥65 years 641 243 (37.9) 52 (8.1) 27 (4.2) 217 (33.9)
Age<65 years 1819 331 (18.2) 90 (4.9) 24 (1.3) 272 (15.0)
With HTN 940 340 (36.2) 75 (8.0) 34 (3.6) 303 (32.2)
Without HTN 1520 234 (15.4) 67 (4.4) 17 (1.1) 186 (12.2)
Values in parentheses are percentages. HTN indicates hypertension; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction.
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from a multiple biomarker panel (consisting of GDF 15, ST2,
and hsTnI) in this cohort,17 we focused on their screening
yield over risk factors and BNP.
Biological Pathways/Biomarkers and LV
Dysfunction and LV Hypertrophy
All 3 cardiac stress biomarkers that were evaluated, along
with BNP, have been associated prospectively with incident
HF and with adverse outcomes in patients with overt HF.26–36
There is substantial experimental evidence that also impli-
cates these biomarkers in LV remodeling. Both ST2 and GDF
15 are anti-hypertrophic, with GDF-15 also being anti-
apoptotic and having anti-inﬂammatory properties.37–42 hsTnI
is an intrinsic myocyte protein, whose levels are associated
with myocyte turnover. Furthermore, all 4 biomarkers mirror
myocyte stretch in basic studies.40,43,44 It is conceivable that
they may also reﬂect other forms of stress, including but not
limited to inﬂammatory, oxidant, or bioenergetic stress.
Therefore, it is not surprising that levels of these biomarkers
so strongly predict HF onset in the community.17 We
demonstrated the association between GDF-15 and hsTnI
with the composite outcome, and with LVSD and LVH,
respectively. Of note, ST2 was not associated with any
outcome. We speculate that the association of ST2 with
incident heart failure may be because it reﬂects systemic
inﬂammation or vascular stiffness or other pathways to heart
failure other than cardiac remodeling.
Strengths and Limitations
The present study included a community-based sample from a
large epidemiological study, used echocardiographic mea-
surements with excellent reproducibility, and studied a panel
of biomarkers for screening for LVSD and LVH, assessing also
a composite outcome that would capture precursors of both
HFPEF and HFREF. Several limitations of the present study
merit consideration. The composite outcome we chose was
most amenable to analyses with adequate statistical power
and corresponds to Stage B heart failure. However, our
analyses of the important outcome of moderate/severe LVSD
(a trait for which deﬁnitive treatment strategies have been
delineated in controlled trials and guidelines) were limited by
the low prevalence of the condition. Additionally, we were not
able to use the quantitative estimation of 2D LVEF to deﬁne
LVSD, as it was not performed routinely during the Offspring
Cohort 6th examination cycle. The generalizability of our
ﬁndings is limited by the use of white, middle- to older-age
Table 7. Incremental Utility of Biomarkers Over Clinical Risk Factors and BNP Within Clinical Subgroups
Composite LVH_80 LVSD_MILDGR
With MI
NRI 0.580 (0.133, 1.028) 0.834 (0.429, 1.239) 0.276 (0.161, 0.713)
P Value for NRI 0.018 0.0002 0.220
Without MI
NRI 0.178 (0.081, 0.275) 0.225 (0.124, 0.326) 0.297 (0.096, 0.498)
P Value for NRI 0.0004 0.00002 0.004
≥65 years
NRI 0.084 (0.075, 0.243) 0.227 (0.066, 0.389) 0.260 (0.022, 0.541)
P Value for NRI 0.305 0.006 0.073
<65 years
NRI 0.274 (0.156, 0.392) 0.281 (0.154, 0.409) 0.202 (0.01, 0.413)
P Value for NRI 0.00001 0.00002 0.062
With HTN
NRI 0.246 (0.114, 0.378) 0.306 (0.172, 0.441) 0.270 (0.035, 0.505)
P Value for NRI 0.0003 0.00001 0.025
Without HTN
NRI 0.128 (0.011, 0.266) 0.173 (0.021, 0.324) 0.112 (0.132, 0.356)
P Value for NRI 0.073 0.027 0.371
Values represent net reclassiﬁcation improvement (NRI) and P-values for comparison between a model including risk factors plus BNP and a model including risk factors, BNP, and novel
biomarkers. We did not observe any statistically signiﬁcant change in the C-statistic between these models; therefore we did not report data on the C-statistic. BNP indicates B-type
natriuretic peptide; HTN, hypertension; LVH, left ventricular hypertrophy; LVSD, left ventricular systolic dysfunction; LVSD_MILDGR, mild/greater LVSD.
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participants of European ancestry. We used a composite
echocardiographic outcome as the primary phenotype for
analyses and reported all statistical tests conducted (even if
nonsigniﬁcant) to address multiple statistical testing issues;
results of secondary analyses may be considered hypothesis
generating. Furthermore, the choice of the cut points for
deﬁning LVH was based on the sex-speciﬁc distribution of LV
mass. However, using the ASE cut points produced essentially
similar results (Tables 8 and 9). Additionally, we did not split
our sample into test and validation samples. Accordingly,
replication of our results in external cohorts would be
desirable. Finally, some risk factors were modeled as
categorical variables (reﬂecting common clinical practice).
Furthermore, we did not include electrocardiographic ﬁndings
as a risk factor for LVH because of prior investigations
suggesting limited accuracy of the electrocardiogram for
detecting LVH.45 It is conceivable that modeling the risk
factors as continuous variables and adjusting for electrocar-
diographic LVH would reduce the incremental predictive utility
of the biomarkers.46 We are aware of the inherent limitation
of the continuous NRI that captures minor shifts in probabil-
ities of outcomes and may be challenging to interpret in terms
of clinical utility.47 We chose it over the categorical NRI in the
absence of clinically meaningful categories for the echocar-
diographic outcomes. Additionally, whereas sensitivity and
speciﬁcity are the metrics often used to assess screening
tests, it is challenging to estimate these indices when a
combination of biomarkers is used for this purpose. Finally,
the central premise of our investigation is that screening with
biomarkers is likely to be less expensive than standard
echocardiography (eg, BNP assays cost $40 or less whereas
an echocardiogram may be 10 times more expensive),48
However, the advent of high-quality, hand-held echocardiog-
raphy may reduce the gap in costs of biomarker assays versus
that of echocardiography.49
Conclusions
In our large community based-sample, GDF-15 and hsTnI were
associated with the composite echocardiographic outcome,
and with LVSD and LVH, respectively. These biomarkers also
offered limited incremental predictive utility over clinical risk
factors and BNP for identifying stage B HF. However, the
clinical signiﬁcance of the modest NRI values remains unclear,
thereby rendering it challenging to advocate the use of these
novel biomarkers for screening purposes in clinical practice.
Additional studies of larger multi-ethnic cohorts are warranted
to conﬁrm our results and further investigations are needed to
elucidate the clinical signiﬁcance of modest NRI values (which
may be statistically signiﬁcant).
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